Legend Biotech Reports Overall Survival Results Of Landmark Phase 3 CARTITUDE-4 Trial In Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech Corporation (NASDAQ:LEGN) announced positive overall survival results from its Phase 3 CARTITUDE-4 trial for CARVYKTI® in multiple myeloma patients. The trial showed significant improvement in overall survival compared to other treatments, with no new safety concerns.
July 02, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's Phase 3 CARTITUDE-4 trial for CARVYKTI® showed significant improvement in overall survival for multiple myeloma patients, with no new safety concerns. This positive result could boost investor confidence and potentially increase the stock price.
The positive results from the Phase 3 trial are likely to boost investor confidence in Legend Biotech's product pipeline, potentially leading to an increase in stock price. The lack of new safety concerns further strengthens the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100